CD8-Targeted, Integrating Viral Vectors Transduce Resting T Cells and Enable Extracorporeal Delivery (ECD) for Rapid CAR T Cell TherapiesJesse Green, Terry J. Fry, Adam Johnson et al.|Blood|2022Cited by 5
Hypoimmune, Allogeneic CD22-Directed CAR T Cells That Evade Innate and Adaptive Immune Rejection for the Treatment of Large B Cell Lymphoma Patients That Are Relapsed/Refractory to CD19-Directed CAR T Cell TherapyAdam Johnson, Terry J. Fry, Hallee Wright et al.|Blood|2023Cited by 4
A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen EscapeAdam Johnson, Aaron E. Foster, Hallee Wright et al.|Blood|2022Cited by 2
BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor ModelsJeremy M. Kinder, Aaron E. Foster, Chanel Athena-Estrada et al.|Blood|2022Cited by 1
Abstract 2735: Development of a novel, fully human anti-CD19 chimeric antigen receptor for <i>in vivo</i> delivery via CD8-targeted fusosomeJeremy M. Kinder, Aaron E. Foster, Christie Ciarlo et al.|Cancer Research|2023Cited by 0